BRIEF-U.S. FDA clears Pluristem's Phase III study of PLX-PAD cells for treatment of critical limb ischemia
Jan 10 Pluristem Therapeutics Inc
* Pluristem's Phase III study of PLX-PAD cells for the treatment of critical limb ischemia cleared by U.S. FDA
* Pluristem expects to begin enrolling patients in its Phase III study in both U.S. and Europe during first half of 2017 Source text for Eikon: Further company coverage:
South Africa's Gordhan to court investors in Britain, U.S.
JOHANNESBURG, March 25 South African Finance Minister Pravin Gordhan embarks on a week-long non-deal investor roadshow in Britain and the United States on Monday as weak economic growth and ruling party tensions put the country's investment grade at risk.
Chinese court rules in favour of Apple in local design patent disputes
BEIJING, March 25 A Chinese court has ruled in favour of Apple in design patent disputes between the Cupertino, California company and a domestic phone-maker, overturning a ban on selling iPhone 6 and iPhone 6 Plus phones in China, Xinhua news agency reported.